Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 65Neoplasms 10Neoplasm Metastasis 9Kidney Neoplasms 7Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Clear-cell metastatic renal cell carcinoma 4Breast Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 2Financial Stress 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Patient Preference 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Oncocytoma, renal 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

enzalutamide 2sipuleucel-T 1pazopanib 1capivasertib 1Watchful Waiting 1STA 9090 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Dutasteride 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of the Prostate × pazopanib × Genitourinary × Clear all
NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

University of Utah

Phase 2 Completed
30 enrolled 10 charts
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡